ADMINISTRATION INFORMATION

Title

Effectiveness of Second-Line Treatments for Unresectable Advanced or Recurrent Soft

Tissue Sarcomas: A Systematic Review and Network Meta-Analysis

Registration

In accordance with the guidelines, our systematic review protocol was registered with

the International Prospective Register of Systematic Reviews (PROSPERO) on 28

September 2025 (registration number CRD420251156600).

Authors

Yosuke Nakano[1], Satoko Zenitani[2], Makoto Endo[3], Takahiro Mihara[1]

[1] Department of Health Data Science, Yokohama City University Graduate School of

Data Science, Yokohama, Japan

[2] Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan

[3] Department of Orthopaedic Surgery, Kyushu University Hospital, Fukuoka, Japan

Corresponding Author

Yosuke Nakano,
Contact: vezzu535@gmail.com

Amendments

Version 1.1, 3rd, November 2025

Funding/ Support

This research did not receive any specific grants from funding agencies in the public,

commercial, or not-for-profit sectors.

Conflict of interest statement

None declared.

ABSTRACT

Introduction:

Soft tissue sarcomas (STS) are rare malignancies with diverse histological subtypes

and an incidence of approximately 40 cases per million annually. Although several

agents, including pazopanib, trabectedin, and eribulin, have been approved in Japan

since 2012 for patients previously treated with anthracyclines, clinical guidelines

provide no consistent recommendations regarding second-line regimens. Given the

lack of head-to-head evidence, treatment selection largely depends on clinician

discretion. This study aims to evaluate the comparative efficacy of second-line

pharmacological regimens for unresectable, advanced, or recurrent STS through a

systematic review and network meta-analysis (NMA).

Methods and analysis:

Randomized controlled trials (RCTs), including multi-arm designs, will be identified

through comprehensive searches of MEDLINE (via PubMed), Embase (via Elsevier),

CENTRAL, WHO ICTRP, and ClinicalTrials.gov from inception to the search date,

without language restrictions. Two reviewers will independently screen records,

extract data, and assess risk of bias using the Cochrane RoB 2 tool; discrepancies will

be resolved by a third reviewer. Pairwise meta-analyses will be performed using

random-effects models, followed by a frequentist NMA with between-study variance

estimated by REML. Consistency will be assessed using design-by-treatment

interaction models (global) and node-splitting methods (local). Treatment ranking will

be evaluated using P-scores or SUCRA. Certainty of evidence for each outcome will

be assessed using CINeMA in line with the GRADE framework.

Support/ Funding:

This research did not receive any specific grants from funding agencies in the public,

commercial, or not-for-profit sectors.

Ethics and dissemination:

This systematic review and network meta-analysis will be conducted using data

extracted from previously published studies and trial registries. As no individual

patient data will be collected or used, ethical approval is not required.

The findings of this review will be disseminated through publication in a

peer-reviewed journal and presentation at relevant scientific conferences. The results

will also be shared with clinicians, policymakers, and researchers to inform clinical

practice and future research.

Where appropriate, the review protocol will be registered in PROSPERO, and the final

dataset and analytic code may be made available in an open-access repository to

ensure transparency and reproducibility.

PROSPERO Registration number: CRD420251156600

Keywords

Soft Tissue Sarcoma; Second-line Therapy; Salvage Therapy; Network Meta-Analysis;

Randomized Controlled Trials

1. Background

Soft tissue sarcomas (STS) are rare malignancies comprising numerous histological subtypes, including liposarcoma and synovial sarcoma, with an incidence of approximately 40 cases per million population annually. In Japan, the Nationwide Bone and Soft Tissue Tumor Registry has been conducted since the 1960s; between 2006 and 2015, 47,852 soft tissue tumors were registered, of which 12,608 were malignant. The five most common subtypes were liposarcoma (4,868 cases), undifferentiated pleomorphic sarcoma (2,584 cases), myxofibrosarcoma (959 cases), leiomyosarcoma (944 cases), and synovial sarcoma (690 cases) (1).

Several new agents have been approved in Japan for previously treated STS since 2012, including pazopanib, trabectedin, and eribulin, all based on trials enrolling patients with prior anthracycline therapy. Although an investigator-initiated comparative study is ongoing domestically, no results have been reported as of August 2025 (2).

The Japanese Clinical Practice Guideline for Soft Tissue Tumors 2020 suggests systemic therapy for unresectable, advanced, or recurrent STS (recommendation grade 2, level C), with doxorubicin monotherapy recommended as first-line (grade 1, level B). Combination therapy with doxorubicin and ifosfamide may be considered when tumor shrinkage is clinically required. For second-line therapy, however, the guideline only notes that the choice depends on histological subtype and treatment goal, without specifying regimens (1). The NCCN Guidelines similarly recommend anthracycline-based regimens first-line, while listing pazopanib, eribulin, trabectedin, and gemcitabine plus docetaxel as category 2A options in subsequent lines (3).

Although certain histologies have drug-specific recommendations, no guideline clearly

indicates preferred regimens for second-line STS. In Japan, despite the availability of

pazopanib, trabectedin, and eribulin, treatment selection largely depends on the

discretion of individual clinicians (1–3).

The rationale for this study is to evaluate the comparative efficacy of pazopanib,

trabectedin, eribulin, and other regimens used after anthracycline therapy through a

systematic review and network meta-analysis, thereby providing evidence to support

clinical decision-making.

2. Objectives

To identify effective second-line pharmacological treatment regimens from the

perspective of disease control in patients with unresectable, advanced, or recurrent soft

tissue sarcoma previously treated with anthracycline-based chemotherapy.

2.1.Primary Objective

To determine the treatment regimen that contributes most to improving overall

survival (OS).

2.2.Secondary Objectives

2.2.1. Progression-Free Survival (PFS)

To determine the treatment regimen that contributes most to prolonging PFS.

2.2.2. Objective Response Rate (ORR)

To identify the treatment regimen associated with the highest ORR.

2.2.3. Local Recurrence-Free Interval (LRFI)

To determine the treatment regimen that contributes most to prolonging LRFI.

2.2.4. Distant Recurrence-Free Interval (DRFI)

To determine the treatment regimen that contributes most to prolonging DRFI.

2.2.5. Histology-Specific OS

To determine the treatment regimen that contributes most to improving OS within each

histological subtype. Subtypes will be classified into six groups: the five most

common histologies and all others combined. Classification will follow the categories

used in each original study.

2.2.6. Histology-Specific PFS

To determine the treatment regimen that contributes most to prolonging PFS within

each histological subtype, following the same classification as in 2.2.5.

2.2.7. Histology-Specific ORR

To identify the treatment regimen associated with the highest ORR within each

histological subtype, following the same classification as in 2.2.5.

2.2.8. Treatment Discontinuation Rate

To evaluate the discontinuation rate for each treatment regimen, regardless of the

reason for discontinuation. Regimens resumed after a temporary pause will not be

considered discontinued.

3. PICO

3.1.Participants

· Patients with unresectable, advanced, or recurrent soft tissue sarcoma

· History of prior anthracycline-based chemotherapy as first-line treatment

· Aged 18 years or older

3.2.Interventions

· Any pharmacological treatment, including chemotherapy, molecular targeted

therapy, or immune checkpoint inhibitors

3.3.Comparators

· Each intervention compared against other interventions

3.4.Outcomes

· Outcomes listed in Section 2 (Objectives): OS, PFS, ORR, LRFI, DRFI,

histology-specific OS, histology-specific PFS, histology-specific ORR, treatment

discontinuation rate, etc.

3.5.Exclusion Criteria

· Trials including patients with osteosarcoma*, chondrosarcoma*, plasmacytoma,

chordoma, Ewing sarcoma, rhabdomyosarcoma, Kaposi's sarcoma, or

gastrointestinal stromal tumor (GIST), carcinosarcoma

(*except for extraskeletal osteosarcoma and extraskeletal myxoid

chondrosarcoma, which will be included)

· Trials in which non-pharmacological therapies (e.g., hyperthermia, radiotherapy)

are included in the treatment regimen

· Trials in which molecular targeted therapies based on molecular diagnosis (e.g.,

ALK inhibitors, NTRK inhibitors) are included in the treatment regimen

· Trials in which different routes, schedules, or doses are compared within the same

drug regimen

4. METHODS

This protocol was developed in accordance with international reporting guidelines for systematic reviews and network meta-analyses, specifically the PRISMA statement (4,5), PRISMA-P (6), and PRISMA-NMA (7).

4.1.Types of studies

This review will include randomized controlled trials (RCTs), including both two-arm and multi-arm trials.

Blinding (e.g., open-label, double-blind) will not be considered as an eligibility criterion. Cluster RCTs will be included only if statistical adjustments for clustering are reported or can be derived.

Crossover trials will be included only if data prior to the crossover are available.

Non-randomized trials, observational studies, single-arm trials, case reports, and case series will be excluded.

Conference abstracts will be included only if they provide sufficient methodological information and outcome data; otherwise, they will be excluded but may be used for citation tracking.

No language restrictions will be applied. Where possible, automatic translation will be used for inclusion; if exclusion occurs due to resource limitations, this will be documented.

4.2.Search methods for identification of studies

We will search the following databases from inception to the date of the search, without language restrictions:

- MEDLINE (via PubMed)
- Embase (via ProQuest)
- Cochrane Central Register of Controlled Trials (CENTRAL)

· WHO International Clinical Trials Registry Platform (ICTRP)

· ClinicalTrials.gov

Search strategies will be developed using a combination of controlled vocabulary

terms (e.g., MeSH, Emtree) and free-text keywords. The PubMed strategy will be

adapted for use in each database. Full search strategies for all databases will be

provided in the Appendix.

For unpublished or ongoing studies identified through trial registries, we will contact

the principal investigators or study sponsors to obtain additional information where

possible.

4.3. Selection of studies

Two reviewers (YN and SZ) will independently screen titles and abstracts and

subsequently assess full texts for eligibility. Any disagreements will be resolved

through discussion or, if necessary, adjudication by a third reviewer (ME).

The first stage of screening will assess eligibility based on titles and abstracts,

followed by a second stage involving full-text review. Reasons for exclusion at the

full-text screening stage will be documented.

Reference management will be conducted using software such as EndNote or

Paperpile, and screening will be performed using tools such as Rayyan. The final

library will be consolidated and stored in formats such as Research Information

Systems (RIS) or National Library of Medicine Bibliographic (NBIB).

Before formal screening, a pilot test will be conducted using a randomly selected

subset of studies.

4.4. Data extraction and management

Two reviewers (YN and SZ) will independently extract data using a standardized form.

The predefined items to be extracted are as follows:

- Trial identifiers (first author, year of publication, country, trial ID, funding source, etc.)
- Study design (parallel-group, multi-arm, blinding, etc.)
- Participant characteristics (median age, sex, ECOG performance status, histological subtype, prior treatments, etc.)
- Intervention details (drug name, regimen, treatment duration, etc.)
- Outcome data (hazard ratios, number of events, follow-up duration, etc.)

In cases where multiple reports originate from the same study, data will be handled as follows:

For studies with multiple publications (e.g., interim and final reports), time-to-event outcomes will be extracted from the report with the longest follow-up, while additional outcomes not included in the final report may be taken from other publications. Outcome-specific source references will be recorded.

Data will be managed using spreadsheet software such as Microsoft Excel. The extraction form will be pilot tested on a small sample of studies prior to full data extraction and refined as necessary.

For missing data, we will attempt to contact the study authors. If the information cannot be obtained, the study will be excluded from the relevant outcome analysis, or alternative approaches such as reconstruction from Kaplan–Meier curves will be considered. Sensitivity analyses will be conducted to assess the impact of missing data.

If additional exploratory items are identified during the review process, they will be

recorded in the protocol and handled separately from the predefined items.

4.5.Assessment of risk of bias

Risk of bias will be assessed for each outcome using the Cochrane Risk of Bias 2

(RoB 2) tool (8). Two reviewers will perform the assessment independently, and any

disagreements will be resolved by discussion or, if necessary, adjudication by a third

reviewer (ME).

In addition, bias specific to network meta-analysis due to missing evidence will be

assessed using the Risk of Bias due to Missing Evidence in Network Meta-analysis

(ROB-MEN) tool (9). The risk of missing evidence will first be examined for each

pairwise comparison and then synthesized across the entire network.

All assessments will be conducted independently by two reviewers for each outcome,

with discrepancies resolved through consultation with a third reviewer (ME).

4.6.Measures of treatment effect

Depending on the type of outcome, the following effect measures will be used. In all

analyses, effect estimates will be oriented so that greater efficacy or lower risk is

expressed as a positive effect.

4.6.1. Time-to-event outcomes (OS, PFS, LRFI, DRFI, etc.)

For time-to-event outcomes, the effect measure will be the hazard ratio (HR) with 95%

confidence intervals (95% CI). Reported HRs from each trial will be used when

available. If not reported, HRs will be reconstructed from Kaplan–Meier curves,

number of events, follow-up periods, or other available data using established methods

(e.g., Parmar method, Tierney method).

Analyses will, in principle, be based on the intention-to-treat (ITT) population.

4.6.2. Binary outcomes (ORR, treatment discontinuation, etc.)

For binary outcomes, the effect measure will be the risk ratio (RR) with 95%

confidence intervals (95% CI). Sensitivity analyses using odds ratios (ORs) will be

conducted as necessary.

The denominator will be based on the intention-to-treat (ITT) population.

4.7.Data synthesis

We will first perform pairwise meta-analyses for each intervention comparison to

evaluate effect estimates and heterogeneity derived from direct comparisons.

Subsequently, a network meta-analysis (NMA) will be conducted to integrate evidence

across the entire network (10).

4.7.1. Pairwise meta-analysis

For each intervention comparison, pooled estimates will be calculated using a

random-effects model. Depending on the outcome, effect measures will include hazard

ratios (HRs), risk ratios (RRs), odds ratios (ORs), or mean differences

(MDs)/standardized mean differences (SMDs), with 95% confidence intervals (95%

CIs).

Statistical heterogeneity will be assessed using the I^2 statistic and τ^2, and prediction

intervals will also be reported. We will interpret I^2 values of approximately 25%, 50%,

and 75% as representing low, moderate, and high heterogeneity, respectively (10).

Clinical and methodological heterogeneity will additionally be considered.

4.7.2. Network meta-analysis

A frequentist network meta-analysis (NMA) based on a random-effects model will be

conducted using R packages such as netmeta and metafor. Between-study variance (τ^2)

will be estimated using restricted maximum likelihood (REML). For multi-arm trials,

correlations will be accounted for using a variance–covariance matrix derived from

Rücker's method (11).

Consistency across the entire network will be assessed globally using the

design-by-treatment interaction test and locally using the node-splitting method.

Treatment ranking will be evaluated using P-scores or the surface under the

cumulative ranking curve (SUCRA) (12,13).

4.7.3. Publication bias and small-study effects

To assess publication bias and small-study effects, we will construct

comparison-adjusted funnel plots by re-expressing the entire network relative to a

common comparator, and test for asymmetry using Egger's regression (10). Begg's

test will also be used as a sensitivity analysis if necessary. In addition, we will

cross-check against clinical trial registries (WHO ICTRP, ClinicalTrials.gov) to

identify unpublished studies.

4.8.Subgroup and sensitivity analysis

The following prespecified subgroup analyses will be conducted:

· By histological subtype (e.g., liposarcoma, leiomyosarcoma, synovial sarcoma)

· By patient characteristics (e.g., age group, prior exposure to ifosfamide)

Subgroup analyses will be performed only when sufficient data are available.

Additionally, if adequate data are reported at the trial level, exploratory

meta-regression analyses will be conducted to examine potential effect modifiers such

as histological distribution, line of therapy, and performance status.

Sensitivity analyses will be performed under the following conditions:

· Excluding trials judged to be at high risk of bias

313   · Excluding trials reporting time-to-event outcomes solely from Kaplan–Meier

314   curves

4.9.Assessment of transitivity and inconsistency

To assess transitivity, we will examine the distribution of potential effect modifiers

(e.g., histological distribution, line of therapy, performance status) across comparisons.

If substantial differences in these distributions are judged to be clinically inappropriate,

the corresponding comparisons will be excluded or combined.

Assessment of inconsistency will be conducted as follows:

· Global assessment: using the design-by-treatment interaction model

· Local assessment: using the node-splitting method

If inconsistency is identified, additional sensitivity or subgroup analyses will be

performed to explore potential sources.

4.10.   Assessment of the certainty of evidence

We will assess the certainty of evidence for each outcome using CINeMA (Confidence

in Network Meta-Analysis) (14). The following six domains will be evaluated:

1. Within-study bias (bias within individual trials)

2. Reporting bias (including publication and selective reporting bias across

studies)

3. Indirectness

4. Imprecision

5. Heterogeneity

6. Incoherence

In addition, following the extension of the GRADE approach to network meta-analysis,

results will be presented as Summary of Findings tables for each outcome.

5. Appendix

5.1.Search strategy for MEDLINE & PubMed Central

Search	Query
#1	"Sarcoma" [MeSH] OR "Soft Tissue Neoplasms" [MeSH] OR "Neoplasms, Connective and Soft Tissue"[MeSH] OR "Soft Tissue Sarcoma" [tiab] OR "STS" [tiab] OR "Sarcoma" [tiab]
#2	"Neoplasm Recurrence, Local"[MeSH] OR "Neoplasm Metastasis"[MeSH] OR "Neoplasm, Residual"[MeSH] OR "unresectable" [tiab] OR "advanced" [tiab] OR "recurrent" [tiab] OR "metastatic" [tiab] OR "locally advanced"[tiab]
#3	#1 and #2
#4	"drug therapy"[Subheading] OR "chemotherapy"[tiab] OR "systemic therapy"[tiab] OR "second-line"[tiab] OR "salvage therapy"[tiab] OR "targeted therapy"[tiab] OR "pharmacotherapy"[tiab] OR "immune checkpoint inhibitor*"[tiab] OR "PD-1 inhibitor*"[tiab] OR "PD-L1 inhibitor*"[tiab] OR "CTLA-4 inhibitor*"[tiab]
#5	"pazopanib"[tiab] OR "trabectedin"[tiab] OR "eribulin"[tiab] OR "gemcitabine"[tiab] OR "docetaxel"[tiab] OR "doxorubicin"[tiab] OR "ifosfamide"[tiab] OR "nivolumab"[tiab] OR "pembrolizumab"[tiab] OR "atezolizumab"[tiab] OR "avelumab"[tiab] OR "durvalumab"[tiab] OR "ipilimumab"[tiab] OR "olaratumab" [tiab] OR "brigimadlin" [tiab]
#6	#4 and #5
#7	(randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR drug therapy[sh] OR randomly[tiab] OR trial[tiab] OR groups[tiab]) NOT (animals[mh] NOT humans[mh])
#8	#3 and #6 and #7

5.2. Search strategy for Cochrane CENTRAL

Search	Query
#1	Sarcoma:ti,ab,kw OR "Soft Tissue Neoplasms":ti,ab,kw OR "Neoplasms, Connective and Soft Tissue":ti,ab,kw OR "Soft Tissue Sarcoma":ti,ab,kw OR STS:ti,ab,kw
#2	"Neoplasm Recurrence, Local":ti,ab,kw OR "Neoplasm Metastasis":ti,ab,kw OR "Neoplasm, Residual":ti,ab,kw OR unresectable:ti,ab,kw OR advanced:ti,ab,kw OR

	recurrent:ti,ab,kw OR metastatic:ti,ab,kw OR "locally advanced":ti,ab,kw
#3	#1 AND #2
#4	chemotherapy:ti,ab,kw OR "systemic therapy":ti,ab,kw OR "second-line":ti,ab,kw OR "salvage therapy":ti,ab,kw OR "targeted therapy":ti,ab,kw OR pharmacotherapy:ti,ab,kw OR ("immune checkpoint" NEAR/1 inhibitor*):ti,ab,kw OR ("PD-1" NEAR/1 inhibitor*):ti,ab,kw OR ("PD-L1" NEAR/1 inhibitor*):ti,ab,kw OR ("CTLA-4" NEAR/1 inhibitor*):ti,ab,kw
#5	pazopanib:ti,ab OR trabectedin:ti,ab OR eribulin:ti,ab OR gemcitabine:ti,ab OR docetaxel:ti,ab OR doxorubicin:ti,ab OR ifosfamide:ti,ab OR nivolumab:ti,ab OR pembrolizumab:ti,ab OR atezolizumab:ti,ab OR avelumab:ti,ab OR durvalumab:ti,ab OR ipilimumab:ti,ab OR olaratumab:ti,ab OR brigimadlin:ti,ab
#6	#4 AND #5
#7	#3 AND #6

343 ## 5.3. Search strategy for Embase via ProQuest

Search	Query
s1	EMB("Sarcoma") OR EMB("Soft Tissue Neoplasms") OR EMB("Neoplasms, Connective and Soft Tissue") OR AB("Soft Tissue Sarcoma") OR TI("Soft Tissue Sarcoma") OR OTI("Soft Tissue Sarcoma") OR AB("STS") OR TI("STS") OR OTI("STS") OR AB("Sarcoma") OR TI("Sarcoma") OR OTI("Sarcoma")
s2	EMB("Neoplasm Recurrence, Local") OR EMB("Neoplasm Metastasis") OR EMB("Neoplasm, Residual") OR AB("unresectable") OR TI("unresectable") OR OTI("unresectable") OR AB("advanced") OR TI("advanced") OR OTI("advanced") OR AB("recurrent") OR TI("recurrent") OR OTI("recurrent") OR AB("metastatic") OR TI("metastatic") OR OTI("metastatic") OR AB("locally advanced") OR TI("locally advanced") OR OTI("locally advanced")
s3	s1 AND s2

s4	EMB("drug therapy") OR AB("chemotherapy") OR TI("chemotherapy") OR OTI("chemotherapy") OR AB("systemic therapy") OR TI("systemic therapy") OR OTI("systemic therapy") OR AB("second-line") OR TI("second-line") OR OTI("second-line") OR AB("salvage therapy") OR TI("salvage therapy") OR OTI("salvage therapy") OR AB("targeted therapy") OR TI("targeted therapy") OR OTI("targeted therapy") OR AB("pharmacotherapy") OR TI("pharmacotherapy") OR OTI("pharmacotherapy") OR AB("immune checkpoint inhibitor*") OR TI("immune checkpoint inhibitor*") OR OTI("immune checkpoint inhibitor*") OR AB("PD-1 inhibitor*") OR TI("PD-1 inhibitor*") OR OTI("PD-1 inhibitor*") OR AB("PD-L1 inhibitor*") OR TI("PD-L1 inhibitor*") OR OTI("PD-L1 inhibitor*") OR AB("CTLA-4 inhibitor*") OR TI("CTLA-4 inhibitor*") OR OTI("CTLA-4 inhibitor*")
s5	TI("pazopanib") OR AB("pazopanib") OR OTI("pazopanib") OR TI("trabectedin") OR AB("trabectedin") OR OTI("trabectedin") OR TI("eribulin") OR AB("eribulin") OR OTI("eribulin") OR TI("gemcitabine") OR AB("gemcitabine") OR OTI("gemcitabine") OR TI("docetaxel") OR AB("docetaxel") OR OTI("docetaxel") OR TI("doxorubicin") OR AB("doxorubicin") OR OTI("doxorubicin") OR TI("ifosfamide") OR AB("ifosfamide") OR OTI("ifosfamide") OR TI("nivolumab") OR AB("nivolumab") OR OTI("nivolumab") OR TI("pembrolizumab") OR AB("pembrolizumab") OR OTI("pembrolizumab") OR TI("atezolizumab") OR AB("atezolizumab") OR OTI("atezolizumab") OR TI("avelumab") OR AB("avelumab") OR OTI("avelumab") OR TI("durvalumab") OR AB("durvalumab") OR OTI("durvalumab") OR TI("ipilimumab") OR AB("ipilimumab") OR OTI("ipilimumab") OR TI("olaratumab") OR AB("olaratumab") OR OTI("olaratumab") OR TI("brigimadlin") OR AB("brigimadlin") OR OTI("brigimadlin")
s6	s4 AND s5
s7	s3 AND s6
s8	EMB.EXPLODE('randomized controlled trial')
s9	EMB('controlled clinical trial')
s10	TI(random*) OR AB(random*) OR OTI(random*)
s11	EMB('randomization')

s12	EMB('intermethod comparison')
s13	TI(placebo) OR AB(placebo) OR OTI(placebo)
s14	TI(compare) OR OTI(compare) OR TI(compared) OR OTI(compared) OR TI(comparison) OR OTI(comparison)
s15	((AB(evaluated) OR AB(evaluate) OR AB(evaluating) OR AB(assessed) OR AB(assess)) AND (AB(compare) OR AB(compared) OR AB(comparing) OR AB(comparison)))
s16	TI(open PRE/1 label) OR AB(open PRE/1 label) OR OTI(open PRE/1 label)
s17	TI((double OR single OR doubly OR singly) PRE/1 (blind OR blinded OR blindly)) OR AB((double OR single OR doubly OR singly) PRE/1 (blind OR blinded OR blindly)) OR OTI((double OR single OR doubly OR singly) PRE/1 (blind OR blinded OR blindly))
s18	EMB('double blind procedure')
s19	TI(parallel PRE/1 group*) OR AB(parallel PRE/1 group*) OR OTI(parallel PRE/1 group*)
s20	(TI(crossover) OR AB(crossover) OR OTI(crossover)) OR (TI('cross over') OR AB('cross over') OR OTI('cross over'))
s21	TI((assign* OR match OR matched OR allocation) NEAR/6 (alternate OR group OR groups OR intervention OR interventions OR patient OR patients OR subject OR subjects OR participant OR participants)) OR AB((assign* OR match OR matched OR allocation) NEAR/6 (alternate OR group OR groups OR intervention OR interventions OR patient OR patients OR subject OR subjects OR participant OR participants)) OR OTI((assign* OR match OR matched OR allocation) NEAR/6 (alternate OR group OR groups OR intervention OR interventions OR patient OR patients OR subject OR subjects OR participant OR participants))
s22	(TI(assigned) OR AB(assigned) OR OTI(assigned)) OR (TI(allocated) OR AB(allocated) OR OTI(allocated))
s23	TI(controlled NEAR/8 (study OR design OR trial)) OR AB(controlled NEAR/8 (study OR design OR trial)) OR OTI(controlled NEAR/8 (study OR design OR trial))
s24	(TI(volunteer) OR AB(volunteer) OR OTI(volunteer)) OR (TI(volunteers) OR AB(volunteers) OR OTI(volunteers))
s25	EMB('human experiment')
s26	TI(trial) OR OTI(trial)

s27	s8 OR s9 OR s10 OR s11 OR s12 OR s13 OR s14 OR s15 OR s16 OR s17 OR s18 OR s19 OR s20 OR s21 OR s22 OR s23 OR s24 OR s25 OR s26
s28	(TI(random* PRE/1 sampl* NEAR/8 ("cross section*" OR questionnaire* OR survey OR surveys OR database OR databases)) OR AB(random* PRE/1 sampl* NEAR/8 ("cross section*" OR questionnaire* OR survey OR surveys OR database OR databases)) OR OTI(random* PRE/1 sampl* NEAR/8 ("cross section*" OR "questionnaire*" OR survey OR surveys OR database OR databases))) NOT (EMB('comparative study') OR EMB('controlled study') OR TI('randomised controlled') OR AB('randomised controlled') OR OTI('randomised controlled') OR TI('randomized controlled') OR AB('randomized controlled') OR OTI('randomized controlled') OR TI('randomly assigned') OR AB('randomly assigned') OR OTI('randomly assigned'))
s29	(EMB('cross-sectional study') NOT (EMB.EXPLODE('randomized controlled trial') OR EMB('controlled clinical study') OR EMB('controlled study') OR TI('randomised controlled') OR AB('randomised controlled') OR OTI('randomised controlled') OR TI('randomized controlled') OR AB('randomized controlled') OR OTI('randomized controlled') OR TI('control group') OR AB('control group') OR OTI('control group') OR TI('control groups') OR AB('control groups') OR OTI('control groups')))
s30	((TI('case control*') OR AB('case control*') OR OTI('case control*')) AND (TI('random*') OR AB('random*') OR OTI('random*')) NOT (TI('randomised controlled') OR AB('randomised controlled') OR OTI('randomised controlled') OR TI('randomized controlled') OR AB('randomized controlled') OR OTI('randomized controlled')))
s31	((TI('systematic review') OR OTI('systematic review')) NOT (TI(trial) OR OTI(trial) OR TI(study) OR OTI(study)))
s32	(TI(nonrandom*) OR AB(nonrandom*) OR OTI(nonrandom*)) NOT (TI(random*) OR AB(random*) OR OTI(random*))
s33	TI('random field*') OR AB('random field*') OR OTI('random field*')
s34	TI('random cluster' NEAR/4 sampl*) OR AB('random cluster' NEAR/4 sampl*) OR OTI('random cluster' NEAR/4 sampl*)

s35	(AB(review) AND RTYPE(review)) NOT (TI(trial) OR OTI(trial))
s36	(AB('we searched') AND (TI(review) OR OTI(review) OR RTYPE(review)))
s37	AB('update review')
s38	AB(databases NEAR/5 searched)
s39	(TI(rat) OR OTI(rat) OR TI(rats) OR OTI(rats) OR TI(mouse) OR OTI(mouse) OR TI(mice) OR OTI(mice) OR TI(swine) OR OTI(swine) OR TI(porcine) OR OTI(porcine) OR TI(murine) OR OTI(murine) OR TI(sheep) OR OTI(sheep) OR TI(lambs) OR OTI(lambs) OR TI(pigs) OR OTI(pigs) OR TI(piglets) OR OTI(piglets) OR TI(rabbit) OR OTI(rabbit) OR TI(rabbits) OR OTI(rabbits) OR TI(cat) OR OTI(cat) OR TI(cats) OR OTI(cats) OR TI(dog) OR OTI(dog) OR TI(dogs) OR OTI(dogs) OR TI(cattle) OR OTI(cattle) OR TI(bovine) OR OTI(bovine) OR TI(monkey) OR OTI(monkey) OR TI(monkeys) OR OTI(monkeys) OR TI(trout) OR OTI(trout) OR TI(marmoset*) OR OTI(marmoset*)) AND EMB('animal experiment')
s40	(EMB('animal experiment') NOT (EMB('human experiment') OR EMB('human')))
s41	s28 OR s29 OR s30 OR s31 OR s32 OR s33 OR s34 OR s35 OR s36 OR s37 OR s38 OR s39 OR s40
s42	s27 NOT s41
s43	s7 AND s42

345 ## 5.4.   Search Strategy for ClinicalTrials.gov

Search	Query
Condition/disease	(Sarcoma OR "Soft Tissue Neoplasms" OR "Soft Tissue Sarcoma" OR STS)
Other terms	(recurrent OR advanced OR unresectable OR metastatic OR "locally advanced")
Intervention/treatment	(chemotherapy OR "systemic therapy" OR "second-line" OR "salvage therapy" OR "targeted therapy" OR pharmacotherapy OR "immune checkpoint inhibitor" OR "PD-1 inhibitor" OR "PD-L1 inhibitor" OR "CTLA-4 inhibitor" OR pazopanib OR trabectedin OR eribulin OR gemcitabine OR docetaxel OR doxorubicin OR ifosfamide OR nivolumab OR pembrolizumab OR atezolizumab OR avelumab OR durvalumab OR ipilimumab OR olaratumab OR brigimadlin)
Other Filters	Age: Adult (18 – 64), Older adult (65+) Study Type: Interventional

346
347 5.5.   Search Strategy for WHO/ICTRP

Search	Query
Title	NA
Condition	(Sarcoma OR "Soft Tissue Neoplasms" OR "Soft Tissue Sarcoma" OR STS)
Intervention	(chemotherapy OR "systemic therapy" OR "targeted therapy" OR "immune checkpoint inhibitor" OR pazopanib OR trabectedin OR eribulin OR gemcitabine OR docetaxel OR doxorubicin OR ifosfamide OR nivolumab OR pembrolizumab OR atezolizumab OR avelumab OR durvalumab OR ipilimumab OR olaratumab OR brigimadlin)
Recruitment status	ALL
Phases	Phase2, Phase3

349   5.6.List of Abbreviations

Abbreviations	Full spell
CENTRAL	Cochrane Central Register of Controlled Trials
DRFI	Distant Relapse Free Interval
GIST	Gastrointestinal Stromal Tumor
GRADE	Grading of Recommendations Assessment, Development, and Evaluation
ICTRP	WHO International Clinical Trials Registry Platform
LRFI	Local Relapse Free Interval
NBIB	National Library of Medicine Bibliographic format
NMA	Network Meta-Analysis
NCCN	National Comprehensive Cancer Network
ORR	Overall Response Rate
OS	Overall Survival
PFS	Progression Free Survival
PRISMA	Preferred Reporting Items for Systematic reviews and Meta-Analyses
PRISMA-P	PRISMA-Protocols
PRISMA-NMA	The PRISMA for network meta-analyses (NMA) extension
REML	Restricted Maximum Likelihood
RIS	Research Information Systems format
RCT	Randomized Controlled Trial
SR	Systematic Review
STS	Soft Tissue Sarcoma

6. References

1. The Japanese Orthopaedic Association, The Japanese Society of Orthopaedic

Oncology. Clinical Practice Guideline for Soft Tissue Tumors 2020. Tokyo:

Nankodo; 2020.

2. Endo M, Kataoka T, Fujiwara T, Tsukushi S, Takahashi M, Kobayashi E, et al.

Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study

JCOG1802: a randomized phase II trial of second-line treatment for advanced

soft tissue sarcoma comparing trabectedin, eribulin and pazopanib. BMC Cancer.

2023 Mar 8;23(1):219.

3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in

Oncology: Soft Tissue Sarcoma, Version 1.2025 [Internet]. Vol. 1. National

Comprehensive Cancer Network (NCCN); 2025 May. Available from:

https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf

4. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting

items for systematic reviews and meta-analyses: the PRISMA statement. PLoS

Med. 2009 July 21;6(7):e1000097.

5. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al.

The PRISMA 2020 statement: an updated guideline for reporting systematic

reviews. BMJ. 2021 Mar 29;372:n71.

6. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al.

Preferred reporting items for systematic review and meta-analysis protocols

(PRISMA-P) 2015 statement. Syst Rev. 2015 Jan 1;4(1):1.

7.   Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al.

The PRISMA extension statement for reporting of systematic reviews

incorporating network meta-analyses of health care interventions: checklist and

explanations. Ann Intern Med. 2015 June 2;162(11):777–84.

8.   Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB

2: a revised tool for assessing risk of bias in randomised trials. BMJ. BMJ; 2019

Aug 28;366:l4898.

9.   Chiocchia V, Nikolakopoulou A, Higgins JPT, Page MJ, Papakonstantinou T,

Cipriani A, et al. ROB-MEN: a tool to assess risk of bias due to missing evidence

in network meta-analysis. BMC Med. 2021 Nov 23;19(1):304.

10. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds).

Cochrane Handbook for Systematic Reviews of Interventions version 6.5

(updated August 2024) [Internet]. Cochrane Handbook. 2024 [cited 2025 Aug 16].

Available from:

https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current

11. Balduzzi S, Rücker G, Nikolakopoulou A, Papakonstantinou T, Salanti G,

Efthimiou O, et al. Netmeta: An *R* package for network meta-analysis using

frequentist methods. J Stat Softw. 2023;106(2):1–40.

12. Jackson D, Barrett JK, Rice S, White IR, Higgins JPT. A design-by-treatment

interaction model for network meta-analysis with random inconsistency effects: A

MODEL FOR NETWORK META-ANALYSIS WITH RANDOM

INCONSISTENCY EFFECTS. Stat Med. 2014 Sept 20;33(21):3639–54.

13. van Valkenhoef G, Dias S, Ades AE, Welton NJ. Automated generation of

node-splitting models for assessment of inconsistency in network meta-analysis.

Res Synth Methods. 2016 Mar;7(1):80–93.

14. Nikolakopoulou A, Higgins JPT, Papakonstantinou T, Chaimani A, Del Giovane

C, Egger M, et al. CINeMA: An approach for assessing confidence in the results

of a network meta-analysis. PLoS Med. 2020 Apr;17(4):e1003082.